|
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)
|
Ongoing
|
Ticagrelor
|
3b
|
D513BC00001
|
King Khalid University Hospital (Riyadh)
|
|
An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
|
|
|
3
|
|
|
|
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
|
|
|
3
|
|
|
|
A multi-center open-label parallel group randomized controlled trial to compare iGlarLixi versus premixed insulin in patients with type 2 diabetes who have failed to achieve glycemic control with basal insulin and oral antidiabetic agents
|
|
|
|
|
|
|
REFINE: Regorafenib observational study in hepatocellular carcinoma
|
|
|
4
|
|
|
|
Use of high dose of Colistin in Multidrug Resistant Gram Negative infections. Randomized Controlled clinical Trial
|
Completed
|
Colistin
|
4
|
KSMC-12-13
|
King Saud Medical City
|
|
"easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment"
|
Rejected
|
-
|
4
|
200104-534
|
King Khalid University Hospital (Riyadh)
|
|
"AN OBSERVATIONAL, NON-INTERVENTIONAL,MULTI-CENTER, MULTI-NATIONAL STUDY OFPATIENTS WITH ATYPICAL HEMOLYTIC-UREMICSYNDROME(AHUS REGISTRY)"
|
Rejected
|
-
|
4
|
M11-001
|
N/A
|
|
A Phase IV Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 month consumption of Vetal Laban Including Lactobacillus acidophilus NCFM on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for A Phase IV, Randomized, double-blind, placebo-controlled study with parallel groups Irritable Bowel Syndrome
|
Rejected
|
Vetal Laban containing Lactobacillus acidophilus NCFM at 1.6 x 109 CFU per container
|
4
|
IBS - 0920
|
King Fahad Medical City (Riyadh)
|
|
"An Open-label, Multicentre, Randomised, 2-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Pregnant Women"
|
Terminated
|
Ferrous Sulphate + Ferinject
|
3
|
FER-ASAP-2009-01
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
